CMB 401

Drug Profile

CMB 401

Alternative Names: anti-PEM monoclonal antibody calicheamicin; CDP 671; hcT.MO1 calicheamicin; hCTMO1-calicheamicin; LLE 33288

Latest Information Update: 02 Feb 2000

Price : $50

At a glance

  • Originator Celltech Group
  • Class Cytostatic antibiotics; Immunotoxins; Monoclonal antibodies
  • Mechanism of Action DNA inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Discontinued Non-small cell lung cancer; Ovarian cancer

Most Recent Events

  • 02 Feb 2000 Medeva has been merged into Celltech Chiroscience, which is now called Celltech Group
  • 16 Dec 1999 Investigation in Non-small cell lung cancer in USA (IV-infusion)
  • 16 Dec 1999 Investigation in Non-small cell lung cancer in United Kingdom (IV-infusion)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top